A Patient Guide — Who Is at Risk, How the Protocol Works, and What to Expect For patients, families, and non-clinician readers IMPORTANT — READ FIRST. This guide explains how the ReBalU protocol is designed to work in plain language. It is not medical advice. It does not replace your doctor.
How Four Antioxidant Loci Already Support Ancestry-Informed Intervention Audience: Practicing physicians, integrative medicine, precision-prevention clinicians Companion whitepapers: Positioning Memo (GMC), East Asian Redox-Reserve, Permutation Matrix, Compound-TT, Lane A/B, Lane C/D Executive Summary The July 19, 2026 New York Times Magazine cover story on the
A biomarker-guided white paper on stress stratification, gut epithelial integrity, microbiome-antioxidant biology, the longevity gene network, and the ReBaLU platform from SOD Sciences Inc. Executive Summary The current social-media cortisol trend is built on an oversimplified idea: that common symptoms such as poor sleep, abdominal weight gain,
The JD Unfiltered 100%-Above-Model Call, the August 2028 Peak, and the −50% China–Japan Crack Anchor: May 1921 = May 2020 | Waypoint reached: 1927 = 2026 (+68 months) | Blow-off peak: August 2028 | Crack: September 2028 — Chinese and Japanese, not American | Recovery: 2029 The Call The 1920s overlay says the
How Rising Westernization Is Overwhelming East Asia's 2,000-Year-Old Dietary Antioxidant Defense Important framing note: The underlying mechanisms cited in this paper are drawn from peer-reviewed literature. The proposed intervention — the ReBalU product and its specific natto-powder and bacteria formulation — rests on non-peer-
How Owned Distribution Lets a Hyperscaler Retrench Into an Apple-Style Moat Meta’s July 2026 pivot into a cloud-compute business — “Meta Compute” — is not an ordinary infrastructure announcement. It is a case study in a repeatable corporate playbook: overbuild → retrench → monetize → distribute. A company that overspends to build
A 150-Year Pattern of Productivity Surges and Why Apple Wins the Agentic Age Roughly once a generation, a technology delivers a leap in productivity so large that users would rationally pay far more than they are charged. History is remarkably consistent on who captures that surplus. Not the inventor.
Thoughts, stories and ideas.
Why the Memory-Cost Panic Misses a US-Made Sole-Source Riding the Fastest Infrastructure Buildout of the Decade Last Price ~$6.98 | Market Cap ~$179M | NASDAQ: AMPG RATING: STRONG BUY (Speculative) — Thesis: Sole-US-source x Buy-American law x AI-forced 5G SA acceleration Executive Summary The market
Why Wall Street Has the Memory Story Exactly Backwards and Why Apple Is the Screaming Big-Cap Buy of the AI Era By JD Unfiltered | June 27, 2026 Last Price ~$284 | Street Median Target $293–$315 RATING: STRONG BUY — 12-Mo Base $400 (+41%) | Bull $442 (+56%) | 5-Yr $664–
There is a version of the next few years in which the United States is standing at the front edge of a 1920s-style productivity boom — one built on AI and data-center infrastructure, and financed increasingly through equity and tokenized dollars rather than fragile debt. This paper makes the
How Deposit Flight into USDC and Gold Tokens Forces Yen Decline, Traps the Government in a Refinancing Spiral and Ends the Nikkei Bull Market Executive Summary Japan has crossed a historic financial inflection point. For the first time since the Bank of Japan began compiling comparable data in 2001, bank
AI investors have spent the last two years obsessing over GPUs. But Nvidia's acquisition of Mellanox demonstrated that some of the most valuable assets in the AI stack are the less visible infrastructure layers that move, route, and optimize data rather than just the processors that compute it.
A Precision-Medicine Framework for Redox-Fragile Populations Core thesis: Historic pathogen pressure, including plague, may have shaped population-level immune and redox differences, while modern clinical development remains overly dependent on European-ancestry biology. ReBalU proposes a genotype- and biomarker-guided way to identify redox-fragile individuals and restore
The most expensive stock on Earth might also be the best acquisition currency ever created. Here's why — and where SpaceX should spend it first. The Setup Five days after the largest IPO in history, SpaceX trades at ~$2.7 trillion. At ~94x 2025 revenue, SPCX carries one of
Equity Research Report IPO reference: $135/share (June 11, 2026) — the largest IPO in history ★ RECOMMENDATION: STRONG BUY ★ SpaceX (SPCX) — Reference $135 | Dramatically Undervalued vs. Perfect-Execution Value Our conviction view. We rate SPCX a major BUY. We believe SpaceX will execute. Our perfect-execution scenarios imply a value many
How a Monopoly on Reusable Space Infrastructure Routes the Global Economy Through the United States and Makes SPCX a Generational Long-Term Buy Executive Summary On June 12, 2026, SpaceX went public on the NASDAQ under ticker SPCX at $135 per share, raising a base of ~$75 billion — expandable to
How a quiet iOS update confirmed what I've been writing for a year and what it means for companies, services, and chips. Executive Summary Apple has quietly partnered with SpaceX and T-Mobile to bring Starlink satellite messaging directly to the iPhone through a recent software update, breaking
Thesis Update — The Track Holds Through May, But Stronger. The Supply Build Is Now Three-Sided. The Update in One Line Through May 2026, the 1927 overlay is holding month by month, but running hotter, because AI is a more powerful leadership engine than radio ever was, and because the
The Lowest-Cost Chronic-Disease Aggregation Platform Meets a Structurally Engineered Short Squeeze ★ MAJOR BUY RECOMMENDATION ★ Status: Pre-Catalyst (Nasdaq compliance deadline: June 30, 2026) Executive Summary We rate Vivos Therapeutics (NASDAQ: VVOS) a MAJOR BUY on the strength of two independent and coequal pillars, each of which would justify